Royalty Pharma plc (RPRX) Institutional Ownership & Insider Trading

641 institutions reported holding Royalty Pharma plc shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 74 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

RPRXRoyalty Pharma plcFollow RPRX — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 36.7B
P/E TTM: 34.0
Dividend yield: 1.1%
52-week: —
Next earnings: 4 Nov, in 11 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

641 institutions held 63.8% of the shares. Across filers that reported both quarters, shares held changed +2.1%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	641	367	+2.1%	265	84	157	31
Mar 26	580	353	+0.4%	208	86	162	49
Dec 25	528	357	+6.6%	210	62	118	37
Sep 25	478	329	-2.4%	177	73	115	37
Jun 25	449	342	+6.8%	157	61	139	48
Mar 25	438	304	+0.2%	145	67	136	42
Dec 24	404	320	+2.1%	142	50	125	45
Sep 24	385	307	-14.2%	147	42	108	35

Royalty Pharma plc — questions

Who owns Royalty Pharma plc stock?: 641 institutions reported Royalty Pharma plc shares in 13F filings for the quarter ended 2026-06-30. The largest: MORGAN STANLEY (7.5%), Capital International Investors (6.1%), BlackRock, Inc. (4.8%).
Are Royalty Pharma plc insiders buying or selling?: 74 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Royalty Pharma plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.